Image

Global Uterine Cancer Drug Market – Industry Trends and Forecast to 2030

  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Nov 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Uterine Cancer Drug  Market, By Types (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma, and Uterine Sarcoma), Mechanism of Action (Angiogenesis Inhibitor, Monoclonal Antibody, Mammalian Target of Rapamycin (mTOR) Inhibitor, and Others), Drugs (Bevacizumab, Everolimus, Temsirolimus, Pembrolizumab, and Others), Therapy (Radiation Therapy, Chemotherapy, Hormone Therapy, Immunotherapy, and Targeted Therapy), Treatment (Supportive Care, Surgery and Medication), Route of Administration (Oral, Intravenous and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.

Uterine Cancer Drug Market

Uterine Cancer Drug Market Analysis and Size

Uterine cancer comprises less than 1% of gynecologic malignancies and 2% to 5% of all uterine malignancies. Growing age is the most important risk factor for most cancers. Other risk factors include hormone therapy, metabolic syndrome, obesity, diabetes, reproductive factors, and family history/genetic predisposition. Most cases are diagnosed at an early stage (stage I–II) and are amenable to treatment with surgery alone.  

Data Bridge Market Research analyses a growth rate in the global uterine cancer drug market in the forecast period 2023-2030. The expected CAGR of the global uterine cancer drug market tends to be around 8.50% in the mentioned forecast period. The market was valued at USD 1.92 billion in 2022 and would grow to USD 3.7 billion by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Uterine Cancer Drug Market Scope and Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Types (Endometrial Adenocarcinoma, Adenosquamous Carcinoma, Papillary Serous Carcinoma and Uterine Sarcoma), Mechanism of Action (Angiogenesis Inhibitor, Monoclonal Antibody, Mammalian Target of Rapamycin (mTOR) Inhibitor, and Others), Drugs (Bevacizumab, Everolimus, Temsirolimus, Pembrolizumab, and Others), Therapy (Radiation Therapy, Chemotherapy, Hormone Therapy, Immunotherapy and Targeted Therapy), Treatment (Supportive Care, Surgery and Medication), Route of Administration (Oral, Intravenous and Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

Johnson & Johnson Private Limited (U.S.), Mylan N.V. (U.S.), Sun Pharmaceutical Industries Limited (India), Sanofi S.A.(France), CLOVIS ONCOLOGY (U.S.), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AbbVie Inc. (U.S.), .), Fresenius Kabi AG (Germany), Amneal Pharmaceuticals LLC. (U.S.), Elekta AB (Sweden), Alnylam Pharmaceuticals, Inc(U.S.), Apotex Inc (Canada), Biogen (U.K), Gilead Sciences, Inc (U.S.)

Market Opportunities

  • Growing healthcare infrastructure and policies
  • Increasing demand for anti-angiogenesis therapy

Market Definition

Uterine cancer is a kind of cancer that occurs in the cells' layers that form the lining of the uterus called the endometrium. The prominent symptoms include vaginal bleeding after menopause, pelvic pain, and bleeding between periods. Uterine cancer can be detected at a very early stage as it frequently produces abnormal vaginal bleeding and can be treated effectively by removing the uterus surgically.

Global Uterine Cancer Drug Market Dynamics

Drivers

  • Increase in uterine cancer cases

The increasing prevalence and rising incidence of uterine cancer across the globe are boosting market growth during the forecast period. For instance, according to the World Cancer Research Foundation, uterine cancer is the sixth-most commonly occurring cancer among women and the fifteenth-most commonly occurring cancer among all other cancer cases. 3 out of 100 women are projected to be diagnosed with uterine cancer, as per the National Cancer Institute.

  • Increasing demand for targeted therapy

The increasing demand for targeted therapy showed numerous advantages as it interferes with specific proteins involved in tumorigenesis, focusing on specific molecular changes that stop the growth of numerous cancers. Several major factors influenced the growth of uterine cancer, including the fewer adverse effects of the therapy and the availability of several targeted therapeutics. This boosts market growth.

Opportunities

  • Growing healthcare infrastructure and policies

The presence of a large patient pool, a strong presence of key players, ease of drug availability, well-established healthcare infrastructure, favorable reimbursement policies in the healthcare system, rise in R&D and innovation activities, and higher adoption of advanced therapeutics may create opportunities for the market.    

  • Increasing demand for anti-angiogenesis therapy

Anti-angiogenesis therapy (AAT) seems to be associated with a relatively high response rate in uterine cancer. For instance, Avastin (bevacizumab/BEV) became the first antivascular endothelial growth factor (VEGF) agent approved for cancer patients' treatment by the U.S. FDA. Bevacizumab is often given along with chemotherapy. Still, it can also be given alone, usually after other drug treatments have been tried.

 Restraints/Challenges

  • Side Effects of Chemotherapy

Several side effects are associated with chemotherapy. Effects such as anemia, sore mouth, hair loss, infections, and tiredness are deeply affecting the patients and thus hampering the market growth.

  • High costs will derail the market growth

The huge expenditure associated with these agents hampers the market growth. Several treatments related to the treatment processes include different therapies, surgery and other counselling sessions that hinder the market growth.

This global uterine cancer drug market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global uterine cancer drug market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Uterine Cancer Drug Market Scope

The global uterine cancer drug market is segmented on the basis of type, mechanism of action, drugs, therapy, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Endometrial Adenocarcinoma
  • Adenosquamous Carcinoma
  • Papillary Serous Carcinoma
  • Uterine Sarcoma

Mechanism of Action

  • Angiogenesis Inhibitor
  • Monoclonal Antibody
  • Mammalian Target of Rapamycin (mTOR) Inhibitor
  • Others

Drugs

  • Bevacizumab
  • Everolimus,
  • Temsirolimus
  • Pembrolizumab
  • Others

Therapy

  • Radiation Therapy
  • Chemotherapy
  • Hormone Therapy
  • Immunotherapy
  • Targeted Therapy

Treatment

  • Supportive Care
  • Surgery
  • Medication

Route of Administration

  • Oral
  • Intravenous
  • Others

End User

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Online Pharmacy
  • Retail Pharmacy

Uterine Cancer Drug  Market Regional Analysis/Insights

The global uterine cancer drug market is analysed and market size insights and trends are provided by type, mechanism of action, drugs, therapy, treatment, distribution channel and end-user as referenced above.

The major countries covered in the global uterine cancer drug market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

Asia-Pacific has been witnessing positive growth for the global uterine cancer drug market throughout the forecasted period due to the presence of key generic pharmaceutical companies in this region and the rise in government initiatives and special communities.

North America dominates the market due to the increase in the women population as the disease tends to affect women and the large availability of treatment options.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Uterine Cancer Drug  Market Share Analysis

The global uterine cancer drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global uterine cancer drug market.

Key players operating in the global uterine cancer drug market include:

  • Johnson & Johnson Private Limited (U.S.)
  • Mylan N.V. (U.S.)
  • Sun Pharmaceutical Industries Limited (India)
  • Sanofi S.A.(France)
  • CLOVIS ONCOLOGY (U.S.)
  • Bayer AG (Germany)
  • Lilly (U.S.)
  • Merck & Co., Inc. (U.S.)
  • GSK plc (U.K.)
  • Novartis AG (Switzerland)
  • AbbVie Inc. (U.S.)
  • Fresenius Kabi AG (Germany)
  • Amneal Pharmaceuticals LLC. (U.S.)
  • Elekta AB (Sweden)
  • Alnylam Pharmaceuticals, Inc(U.S.)
  • Apotex Inc (Canada)
  • Biogen (U.K)
  • Gilead Sciences, Inc (U.S.)


SKU-
Why Choose Us


Frequently Asked Questions

The global uterine cancer drug market was USD 1.92 billion in 2021.
The global uterine cancer drug market is projected to grow at a CAGR of 8.50% during the forecast period of 2022-2029.